Cathelicidin peptide LL-37 increases UVB-triggered inflammasome activation: Possible implications for rosacea

Journal of Dermatological Science

Volumn 76, Issue 3, 2014, Pages 173-179

  Salzer, Suzanna ^a   Kresse, Sonja ^a   Hirai, Yoji ^a   Koglin, Sarah ^a   Reinholz, Markus ^a   Ruzicka, Thomas ^a   Schauber, Jürgen ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Angiogenesis; Cathelicidin LL 37; Inflammasome; P2X7; Rosacea; UVB

Indexed keywords

CALCIUM; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; INFLAMMASOME; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; PURINERGIC P2X7 RECEPTOR; ANTIMICROBIAL CATIONIC PEPTIDE; AUTACOID; CAP18 LIPOPOLYSACCHARIDE-BINDING PROTEIN;

ANGIOGENESIS ASSAY; ARTICLE; CALCIUM CELL LEVEL; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE EXACERBATION; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOPATHOGENESIS; INNATE IMMUNITY; KERATINOCYTE; MOLECULAR PATHOLOGY; POLYMERASE CHAIN REACTION; PROTEIN FUNCTION; RADIATION EXPOSURE; ROSACEA; SECOND MESSENGER ASSAY; SKIN BLOOD FLOW; SUN EXPOSURE; ULTRAVIOLET B RADIATION; ADVERSE EFFECTS; CELL CULTURE; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PHYSIOLOGY; RADIATION DOSE; RADIATION RESPONSE; ULTRAVIOLET RADIATION;

ANTIMICROBIAL CATIONIC PEPTIDES; CALCIUM; CELLS, CULTURED; HUMANS; INFLAMMASOMES; INFLAMMATION MEDIATORS; INTERLEUKIN-1BETA; KERATINOCYTES; NEOVASCULARIZATION, PATHOLOGIC; RADIATION TOLERANCE; RECEPTORS, PURINERGIC P2X7; ROSACEA; ULTRAVIOLET RAYS;

EID: 84919492128     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2014.09.002     Document Type: Article

References (45)

1. Tan J., Berg M. Rosacea: current state of epidemiology. J Am Acad Dermatol 2013, 69:S27-S35.
2. Marks R. The enigma of rosacea. J Dermatolog Treat 2007, 18:326-328.
3. Powell F.C. Clinical practice. Rosacea. N Engl J Med 2005, 352:793-803.
4. Elewski B.E., Draelos Z., Dreno B., Jansen T., Layton A., Picardo M. Rosacea-global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group. J Eur Acad Dermatol Venereol 2011, 25:188-200.
5. Crawford G.H., Pelle M.T., James W.D., Rosacea: I.Etiology, pathogenesis, and subtype classification J Am Acad Dermatol 2004, 51(327):41. (quiz 342-4).
6. Steinhoff M., Buddenkotte J., Aubert J., Sulk M., Novak P., Schwab V.D., et al. Clinical, cellular, and molecular aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc 2011, 15:2-11.
7. Coda A.B., Hata T., Miller J., Audish D., Kotol P., Two A., et al. Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel. J Am Acad Dermatol 2013, 69:570-577.
8. Zhang J., Xu X., Rao N.V., Argyle B., McCoard L., Rusho W.J., et al. Novel sulfated polysaccharides disrupt cathelicidins, inhibit RAGE and reduce cutaneous inflammation in a mouse model of rosacea. PLoS One 2011, 6:e16658.
9. Yamasaki K., Gallo R.L. Rosacea as a disease of cathelicidins and skin innate immunity. J Investig Dermatol Symp Proc 2011, 15:12-15.
10. Yamasaki K., Gallo R.L. The molecular pathology of rosacea. J Dermatol Sci 2009, 55:77-81.
11. Yamasaki K., Di Nardo A., Bardan A., Murakami M., Ohtake T., Coda A., et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med 2007, 13:975-980.
12. Fallen R.S., Gooderham M. Rosacea: update on management and emerging therapies. Skin Therapy Lett 2012, 17:1-4.
13. Zanetti M. Cathelicidins, multifunctional peptides of the innate immunity. J Leukoc Biol 2004, 75:39-48.
14. Schauber J., Gallo R.L. Antimicrobial peptides and the skin immune defense system. J Allergy Clin Immunol 2008, 122:261-266.
15. Yamasaki K., Schauber J., Coda A., Lin H., Dorschner R.A., Schechter N.M., et al. Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. FASEB J 2006, 20:2068-2080.
16. Koczulla R., von Degenfeld G., Kupatt C., Krotz F., Zahler S., Gloe T., et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest 2003, 111:1665-1672.
17. Ramos R., Silva J.P., Rodrigues A.C., Costa R., Guardao L., Schmitt F., et al. Wound healing activity of the human antimicrobial peptide LL37. Peptides 2011, 32:1469-1476.
18. Morizane S., Gallo R.L. Antimicrobial peptides in the pathogenesis of psoriasis. J Dermatol 2012, 39:225-230.
19. Borkowski A.W., Gallo R.L. The coordinated response of the physical and antimicrobial peptide barriers of the skin. J Invest Dermatol 2011, 131:285-287.
20. Yamasaki K., Kanada K., Macleod D.T., Borkowski A.W., Morizane S., Nakatsuji T., et al. TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes. J Invest Dermatol 2011, 131:688-697.
21. Casas C., Paul C., Lahfa M., Livideanu B., Lejeune O., Alvarez-Georges S., et al. Quantification of Demodex folliculorum by PCR in rosacea and its relationship to skin innate immune activation. Exp Dermatol 2012, 21:906-910.
22. Bauernfeind F., Ablasser A., Bartok E., Kim S., Schmid-Burgk J., Cavlar T., et al. Inflammasomes: current understanding and open questions. Cell Mol Life Sci 2011, 68:765-783.
23. Fan F., Stoeltzing O., Liu W., McCarty M.F., Jung Y.D., Reinmuth N., et al. Interleukin-1beta regulates angiopoietin-1 expression in human endothelial cells. Cancer Res 2004, 64:3186-3190.
24. Garlanda C., Dinarello C.A., Mantovani A. The interleukin-1 family: back to the future. Immunity 2013, 39:1003-1018.
25. Rosell A., Arai K., Lok J., He T., Guo S., Navarro M., et al. Interleukin-1beta augments angiogenic responses of murine endothelial progenitor cells in vitro. J Cereb Blood Flow Metab 2009, 29:933-943.
26. Dombrowski Y., Peric M., Koglin S., Kammerbauer C., Goss C., Anz D., et al. Cytosolic DNA triggers inflammasome activation in keratinocytes in psoriatic lesions. Sci Transl Med 2011, 3:82ra38.
27. Feldmeyer L., Keller M., Niklaus G., Hohl D., Werner S., Beer H.D. The inflammasome mediates UVB-induced activation and secretion of interleukin-1beta by keratinocytes. Curr Biol 2007, 17:1140-1145.
28. Yamasaki K., Muto J., Taylor K.R., Cogen A.L., Audish D., Bertin J., et al. NLRP3/cryopyrin is necessary for interleukin-1beta (IL-1beta) release in response to hyaluronan, an endogenous trigger of inflammation in response to injury. J Biol Chem 2009, 284:12762-12771.
29. Elssner A., Duncan M., Gavrilin M., Wewers M.D. A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1 beta processing and release. J Immunol 2004, 172:4987-4994.
30. Tomasinsig L., Pizzirani C., Skerlavaj B., Pellegatti P., Gulinelli S., Tossi A., et al. The human cathelicidin LL-37 modulates the activities of the P2X7 receptor in a structure-dependent manner. J Biol Chem 2008, 283:30471-30481.
31. Reinholz M., Tietze J.K., Kilian K., Schaller M., Schofer H., Lehmann P., et al. Rosacea-S1 guideline. J Dtsch Dermatol Ges 2013, 11. 768, 780; 768-779.
32. Huggenberger R., Detmar M. The cutaneous vascular system in chronic skin inflammation. J Investig Dermatol Symp Proc 2011, 15:24-32.
33. Chosidow O., Cribier B. Epidemiology of rosacea: updated data. Ann Dermatol Venereol 2011, 138(Suppl 3):S179-S183.
34. Gomaa A.H., Yaar M., Eyada M.M., Bhawan J. Lymphangiogenesis and angiogenesis in non-phymatous rosacea. J Cutan Pathol 2007, 34:748-753.
35. Del Rosso J.Q. Advances in understanding and managing rosacea: Part 1: Connecting the dots between pathophysiological mechanisms and common clinical features of rosacea with emphasis on vascular changes and facial erythema. J Clin Aesthet Dermatol 2012, 5:16-25.
36. Gerber P.A., Buhren B.A., Steinhoff M., Homey B., Rosacea The cytokine and chemokine network. J Investig Dermatol Symp Proc 2011, 15:40-47.
37. Ferrari D., Pizzirani C., Adinolfi E., Lemoli R.M., Curti A., Idzko M., et al. The P2X7 receptor: a key player in IL-1 processing and release. J Immunol 2006, 176:3877-3883.
38. Kahlenberg J.M., Dubyak G.R. Mechanisms of caspase-1 activation by P2X7 receptor-mediated K+ release. Am J Physiol Cell Physiol 2004, 286:C1100-C1108.
39. Inoue K., Hosoi J., Denda M. Extracellular ATP has stimulatory effects on the expression and release of IL-6 via purinergic receptors in normal human epidermal keratinocytes. J Invest Dermatol 2007, 127:362-371.
40. Solle M., Labasi J., Perregaux D.G., Stam E., Petrushova N., Koller B.H., et al. Altered cytokine production in mice lacking P2X(7) receptors. J Biol Chem 2001, 276:125-132.
41. Kahlenberg J.M., Carmona-Rivera C., Smith C.K., Kaplan M.J. Neutrophil extracellular trap-associated protein activation of the NLRP3 inflammasome is enhanced in lupus macrophages. J Immunol 2013, 190:1217-1226.
42. Pastore S., Mascia F., Gulinelli S., Forchap S., Dattilo C., Adinolfi E., et al. Stimulation of purinergic receptors modulates chemokine expression in human keratinocytes. J Invest Dermatol 2007, 127:660-667.
43. Hirakawa S., Fujii S., Kajiya K., Yano K., Detmar M. Vascular endothelial growth factor promotes sensitivity to ultraviolet B-induced cutaneous photodamage. Blood 2005, 105:2392-2399.
44. Rosina P., Zamperetti M.R., Giovannini A., Chieregato C., Girolomoni G. Videocapillaroscopic alterations in erythematotelangiectatic rosacea. J Am Acad Dermatol 2006, 54:100-104.
45. Carretero M., Escamez M.J., Garcia M., Duarte B., Holguin A., Retamosa L., et al. In vitro and in vivo wound healing-promoting activities of human cathelicidin LL-37. J Invest Dermatol 2008, 128:223-236.